Gui B, et al. - Given the limited utility of the Child-Pugh (C-P) class by the subjectivity of ascites and encephalopathy, experts assessed a previously established objective method, the albumin-bilirubin (ALBI) grade, as a prognosticator for yttrium-90 radioembolization (RE) treatment for patients with hepatocellular carcinoma (HCC). Clear survival discrimination was demonstrated by ALBI grade as a prognosticator that is superior to C-P class among HCC patients treated with RE, particularly within the subgroup of C-P class A patients. Findings suggested the utility of ALBI grade for clinicians to make decisions as to whether or not RE should be recommended to patients with HCC.